The last two days have been very exciting. We released a Seeking Alpha article on Rexahn (RNN) when the stock traded at $0.80, and over the past two days it has skyrocketed nearly 30% to $1.05. We hope that you were all able to capitalize on this amazing investment opportunity.
If you haven't read it already, the article is accessible here for 30 days: http://seekingalpha.com/ article/2215513-rexahn- pharmaceuticals-an- undervalued-oncology-play- with-risk-diversification
In light of increasing demand for the newsletter, we are in the process of converting it to a premium subscription service. We are very encouraged by the overwhelming support from our followers and strongly believe in this approach.
Please contact Trevor Lowenthal at tmlowenthal@ucdavis.edu for more information about the transition to a premium subscription service. We are happy to assist in any way possible.
Stay tuned!
No comments:
Post a Comment